Finanzen von XBiotech Inc (XBIT)XBITXBiotech Inc

Evaluating the bottom line, XBiotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.94%, provide a clear picture of how effectively XBIT converts its operational activities into shareholder value.

In the context of the broader market, XBIT competes directly with industry leaders such as NMAD and PLRX. With a market capitalization of $69.21M, it holds a significant position in the sector. When comparing efficiency, XBIT's gross margin of N/A stands against NMAD's N/A and PLRX's N/A. Such benchmarking helps identify whether XBiotech Inc is trading at a premium or discount relative to its financial performance.

XBiotech has reported consistent losses, with a net income loss of $6.7 million in Q2 2026 and a year-over-year decline of 24.83%. The company has a negative EPS of -0.22 for the latest quarter, reflecting ongoing financial struggles.